| Trial ID: | L6242 |
| Source ID: | NCT01068756
|
| Associated Drug: |
Dapagliflozin
|
| Title: |
Effect of Rifampin on the Pharmacokinetics of Dapagliflozin in Healthy Subjects
|
| Acronym: |
|
| Status: |
TERMINATED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes Mellitus
|
| Interventions: |
DRUG: Dapagliflozin|DRUG: Rifampin
|
| Outcome Measures: |
Primary: AUC (area under the concentration-time curve) Single dose pharmacokinetic parameter will be derived from plasma concentration versus time data, Days 1 to 3 and Days 9 to 11 | Secondary: Cmax (maximum observed concentration) Single dose pharmacokinetic parameter will be derived from plasma concentration versus time data, Days 1 to 3 and Days 9 to 11|Tmax (time of maximum observed concentration) Single dose pharmacokinetic parameter will be derived from plasma concentration versus time data, Days 1 to 3 and Days 9 to 11
|
| Sponsor/Collaborators: |
Sponsor: AstraZeneca | Collaborators: Bristol-Myers Squibb
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE1
|
| Enrollment: |
14
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose:
|
| Start Date: |
2010-03
|
| Completion Date: |
2010-04
|
| Results First Posted: |
|
| Last Update Posted: |
2016-10-17
|
| Locations: |
Ppd Development, Austin, Texas, 78744, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT01068756
|
